Teva (TEVA) Provides Update on Generic Aciphex Litigation
More News related to TEVA
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Teva Receives Final Approval for Generic Prevacid(R) Delayed-Release Capsules
- Teva Pharma (TEVA) Announces Generic Version of Prevacid Does Not Infringe on Patents
- Teva Receives Favorable Court Decision Regarding Generic Prevacid(R) SoluTab
- Teva Pharma (TEVA) Seeks to Amend Existing Complaint Against Momenta Pharma over Copaxone Patent Infringement
More News related to Corporate News
- Sypris Solutions (SYPR) Sibsidiary Awarded $200M 5-Year IDIQ Contract from U.S. DoD to Replace KYK-13
- Lockheed Martin (LMT) Awarded 12-Month Contract from DARPA for Next-Gen MDA Technology Development
- Ford Europe (F) Rolls To Higher Sales and Market Share in October
- Citigroup (C) Kelly Making Comments At Banking Conference: "Balance Sheet is Very Liquid"
- Rockwell Collins (COL) Awarded $450M U.S. Navy Contract for ARC-210 Radios
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. District Court for the Southern District of New York has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Eisai's acid pump inhibitor Aciphex (Rabeprazole Sodium) Tablets, 20 mg. The Court found Eisai's U.S. Patent No. 5,045,552 enforceable.
Teva intends to appeal this decision immediately as well as the Court's decision granting to Eisai Summary Judgment of validity.
Related Categories
Corporate NewsStocks Mentioned
-0.25Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
